Results 1 to 10 of about 45,830 (222)
Background: The clinical outcome of breast carcinoma varies in each individual due to its molecular heterogeneity. There is a rising interest in whether the associated ductal carcinoma in-situ in invasive ductal carcinoma of breast affects the prognosis ...
Dhivya Balaiya +2 more
doaj +1 more source
Immunohistochemical Expression of p63 in Benign and Malignant Breast Lesions [PDF]
Introduction: Breast carcinoma demands attention as it causes high morbidity and mortality. It is important to recognise benign lesions to distinguish them from in situ and invasive breast cancer and to assess a patient’s risk of developing breast ...
Abhishek Saini +6 more
doaj +1 more source
The incidence of ductal carcinoma in situ has increased with the rise in screening mammography; currently, ductal carcinoma in situ constitutes 20%–25% of all breast cancers, and up to half of them may become invasive.
Yeon Jung Kim, Hyun Kyung Jung, Woogyeong Kim
doaj +1 more source
Breast Ductal Carcinoma In Situ [PDF]
Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there
V. Sacchini +5 more
openaire +2 more sources
Breast carcinoma is a heterogeneous group of tumors with a wide spectrum of clinical presentations, lesion characterization and diagnostic evaluation.
Ankit Prabhakar +4 more
doaj +1 more source
Potential biomarkers of ductal carcinoma in situ progression
Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni +17 more
doaj +1 more source
Background The upgrade rate of biopsy-confirmed ductal carcinoma in situ (DCIS) to invasive carcinoma is up to 50% on final pathology. We investigated MRI and clinicopathologic predictors of the invasive components of DCIS diagnosed by preoperative ...
Ga Young Yoon +5 more
doaj +1 more source
Purpose To predict ductal carcinoma in situ with microinvasion (DCISMI) based on clinicopathologic, conventional breast magnetic resonance imaging (MRI), and dynamic contrast enhanced MRI (DCE-MRI) radiomics signatures in women with biopsy-confirmed ...
Zhou Huang +4 more
doaj +1 more source
Cystic hypersecretory carcinoma with invasion: Case series on a rare variant of carcinoma breast
Background: Cystic Hypersecretory Carcinoma (CHC) is a rare subset of breast carcinoma. It is part of a spectrum of cystic hypersecretory lesions which includes cystic hypersecretory hyperplasia (CHH), CHH with atypia, CHC in situ and CHC with invasion ...
Hibu Yami +3 more
doaj +1 more source

